背景:生活质量(QoL)已成为评估癌症患者治疗和预后的重要指标。乳腺癌患者在癌症积极治疗期间经历不良QoL的风险增加。本研究旨在使用欧洲癌症研究和治疗组织EORTC乳腺癌特定生活质量问卷QLQ-BR45的最新乳腺癌专用工具评估乳腺癌患者的QoL及其影响因素。
方法:对TikurAnbessa专科医院(TASH)的248例乳腺癌患者进行了一项基于机构的横断面研究。描述性统计,单向方差分析(ANOVA),采用线性回归对数据进行描述和分析。
结果:参与者的全球健康状况/QoL平均得分为65.6。在功能尺度中,未来视角得分最低(57.1,SD±37.3).症状量表/项目的最高平均得分是经济困难(50,SD±38.6),其次是食欲减退(37.4,SD±36.4)和疲劳(34.3,SD±27.1),而症状评分最低的是腹泻(6.4±18.4)。EORTCQLQ-BR45,未来观点(平均值=57.1,SD±37.3)和脱发不适(41.8,SD±34.6)分别是受影响最大的功能和症状量表。肿瘤分期增加与更多的疼痛相关(P=0.041)。食欲减退(P=0.042),和手臂症状(P=0.003)。无合并症的患者体质较好(P<0.001),认知(P=0.013),和社会功能(P=0.009)。
结论:应单独评估这些特定的功能量表和症状,以解决未满足的需求。临床医生可以设计心理社会干预措施来改善这些功能并减轻症状。
BACKGROUND: Quality of life (QoL) has become an important measure for evaluating cancer patients\' treatment and prognosis. Breast cancer patients are at an increased risk of experiencing poor QoL during active treatment of cancer. This study aimed to assess QoL and it\'s influencing factors among breast cancer patients using the newly updated breast cancer specific tool of the European Organisation for Research and Treatment of Cancer EORTC Breast Cancer Specific Quality of Life Questionnaire QLQ-BR45.
METHODS: An institutional based crossectional study was conducted with 248 breast cancer patients at Tikur Anbessa Specialized Hospital (TASH). Descriptive statistics, one-way analysis of variance (ANOVA), and linear regression were used to describe and analyze the data.
RESULTS: The participant\'s Global health status/QoL mean score was 65.6. Among the functional scales, future perspective scored the lowest (57.1, SD ± 37.3). The highest mean score on the symptom scales/items were financial difficulties (50, SD ± 38.6), followed by appetite loss (37.4, SD ± 36.4) and fatigue (34.3, SD ± 27.1) while the lowest symptom score was diarrhoea (6.4 ± 18.4). EORTC QLQ-BR45, future perspective (mean = 57.1, SD ± 37.3) and upset by hair loss (41.8, SD ± 34.6) were the most affected functioning and symptoms scales respectively. An increased stage of tumor was associated with more pain (P = 0.041), appetite loss (P = 0.042), and arm symptoms (P = 0.003). Patients who had no comorbidity had better physical (P < 0.001), cognitive (P = 0.013), and social (P = 0.009) function.
CONCLUSIONS: These specific functional scales and symptoms should be assessed individually to address unmet needs. Clinicians could design psychosocial interventions to improve these function and to reduce symptoms.